Michael S. Amalfe

Michael Amalfe is a partner in Goodwin’s Private Equity group. Michael specializes in representing large cap and middle-market private equity funds and their portfolio companies in a wide variety of complex business transactions, including mergers and acquisitions and dispositions, leveraged buyouts, growth equity financings, venture capital financings, joint venture investments, and carve-outs. He also counsels clients with respect to general corporate and governance matters. Michael advises clients in various industries including consumer products, healthcare, industrials and technology.

Michael’s recent work includes advising:

• Vericast in connection with the sale of its digital and print marketing businesses to R.R. Donnelley & Sons Company*
• Sycamore Partners in its take private acquisition of Chico’s FAS Inc. for $1 billion*
• TJC
  • In its acquisition of an 80.1% stake of resins unit Delrin from DuPont in a transaction that values the business at $1.8 billion*
  • In its acquisition of USAlco from H.I.G. Capital*
  • In its acquisition of LegitScript*
  • In connection with its investment in Flywheel Software*
• Investindustrial
  • In its acquisition of significant portions of the meal preparation business of TreeHouse Foods for $950 million*
  • On the U.S. aspects of its investment in Eataly*
  • In its acquisition of Parker Food Group*
• Altaris Capital
  • In the combination of two of its operating companies, Kindeva Drug Delivery and Meridian Medical Technologies, and the financing of the combined company*
  • In the acquisition of Minaris Regenerative Medicine from Resonac Corporation*
• BC Partners in connection with its acquisition of Madison Logic*
• EW Healthcare Partners in its take-private acquisition of TherapeutricsMD, Inc.*
• Antarctica Capital in its take-private acquisition of Midwest Holding (NASDAQ: MDWT)*
• EQT and its portfolio company Recipharm, a global contract development and manufacturing organization (“CDMO”), on the acquisition of Vibalogics, a virotherapy CDMO and Arranta Bio, a prominent advanced therapy CDMO*
• Hg Capital in the recapitalization of Lyniate*

*Denotes experience prior to joining Goodwin

Prior to joining Goodwin, Michael was a partner at Kirkland & Ellis LLP.